Lundbeck: Reimbursement as expected
Lundbeck’s blockbuster candidate, antidepressant Brintellix, is likely to be given general conditional reimbursement. The recommendation from the Danish Reimbursement Committee is in line with Lundbeck’s own expectations, says the director of Lundbeck Pharma Denmark.
BY BENJAMIN WERNER CHRISTENSEN
The Danish Medicines Reimbursement Committee has recommended Lundbeck’s antidepressant Brintellix for general conditional reimbursement, which gives cause for satisfaction in Lundbeck, however, the Danish drug group is not surprised by the outcome.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Lundbeck’s alcohol pill hits speed bump
For abonnenter
